Abstract ID: A1
Abstract Title: Metalloproteinase Inhibition in Axial Low Back Pain From Animal Model To Clinical Study
Authors: Margolin L
Bronx NY USA
Poster Type: Poster
ABSTRACT BODY
Introduction:
In continuation to our previous presentation we are going to suggest a clinical study based on these animal results.
Matrix metalloproteinases (MMP) are the key enzymes in the pathogenesis of osteoarthritis and inflammatory arthritis. Inhibition of the matrix metalloproteinases has been postulated to block metastasis invasion and to play an important role in the pathogenesis of both non-cancer and cancer chronic pain.
Our study determines the long term effect of metalloproteinase inhibition on extracellular matrix remodeling, cell proliferation and migration in rats. The study was performed on the common carotid artery model because of the good accessibility and reliable injury assessment techniques of this model in comparison to articular cartilage.
Methods: 120 slides from the the common carotid artery of Sabra rats treated with the metalloproteinase inhibitor underwent immunohistochemical staining and histomorphometric evaluation
Results: The absolute number of the BrDU stained cells was significantly lower in the neointima 14, 25, and 75 days after the injury in the group which received combined treatment vs. the control group (p=0.0001, 0.001 and 0.01 respectively). The mean relative intensity of the MMP-2 bands (100±13), measured by computerized densitometry was significantly greater than in control group than in the treated animals.
Conclusion: We found that MMP inhibition resulted in a significant decrease in the cell proliferation and the remodeling of the extracellular matrix up to 2½ months after the MMP injection versus untreated control group and that these effects were associated with a marked reduction in MMP-2 activity. We strongly advocate testing of matrix metalloproteinase inhibitors in larger animals and in the clinical setting as a potential disease modifying agent for non-cancer and cancer chronic pain syndromes.
We are presenting a model for the use of non hydroxamate MMP inhibitor as potential disease modifying agents for axial low back pain and Facet Syndrome.
ATTACHED FILES
Reg Anesth Pain Med 2005; 30(3):A1